Trimeris stock certainly is getting tossed around by analyst ratings.
Bear Stearns became the latest to weigh in on the drug company’s stock on Wednesday, downgrading it to “peer perform” from outperform.
Trimeris stock dropped 2.8 percent on the day to close at $48.37.
Trimeris and partner Roche are bringing to market the new AIDS drug Fuzeon, and on May 28 the firms announced approval by the European Union. That followed on the heels of approval by the FDA in the United States.
SG Cowen initiated coverage on May 28 at “outperform.”
But on June 10, First Albany launched coverage of Trimeris as “neutral.”